ReviewDiagnostics (Basel, Switzerland)2022
Chronic Thromboembolic Pulmonary Hypertension: An Update.
Review in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 46 citations in OpenAlex.
- Artificial Intelligence in Pulmonary Hypertension: Current State and Future Prospects.Reviews in cardiovascular medicine · 2026Review
- Clinical Updates in Pulmonary Hypertension.Reviews in cardiovascular medicine · 2026Review
- Pulmonary Embolism in Antiphospholipid Syndrome (APS)-Where Are We and Where Are We Going?International journal of molecular sciences · 2026Review
- Exploring the therapeutic landscape of pulmonary hypertension associated with interstitial lung disease, with a focus on idiopathic pulmonary fibrosis: a narrative review.Frontiers in pharmacology · 2026Review
- Exploring sarcoidosis via nailfold capillaroscopy: A window into the disease's microvascular landscape.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- Evaluation of Machine Learning Methods Developed for Prediction and Diagnosis of Pneumonia: A Systematic Review.Health science reports · 2025Review
- Inflammation-Based Hematologic Indices as Prognostic Markers in Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension: A Hypothesis-Generating Registry Study.International journal of molecular sciences · 2025Article
- Editorial for "Diagnosis, Classification, and Monitoring of Pulmonary Diseases".Diagnostics (Basel, Switzerland) · 2025Article
- Retrospective Observational Study of Nintedanib in Managing Idiopathic and Progressive Pulmonary Fibrosis in Routine Practice.Journal of clinical medicine · 2025Article
- Assessment of Right Ventricular Pressure in Chronic Thromboembolic Pulmonary Hypertension: Comparison of Diagnostic Modalities and Balloon Pulmonary Angioplasty Outcomes.Diagnostics (Basel, Switzerland) · 2025Article
- Is pulmonary embolism a chronic disease?Clinical medicine (London, England) · 2025Review
- The Role of the Pulmonary Vascular Microenvironment in Chronic Thromboembolic Pulmonary Hypertension.Pulmonary circulation · 2025Review
- What the Interventional Radiologist Needs to Know about Imaging Studies for the Detection, Risk Stratification, and Short- and Long-Term Follow-up of Pulmonary Embolism.Seminars in interventional radiology · 2025Review
- Comorbidities' Effect on IPF: Pathogenesis and Management.Biomedicines · 2025Review
- Pulmonary hypertension aetiologies in different parts of the world.International journal of cardiology. Congenital heart disease · 2025Review
- Chronic thromboembolic hypertension predictors in computed tomography angiography. Single-centre study.Polish journal of radiology · 2025Article
- The use of imaging in the diagnosis and treatment of thromboembolic pulmonary hypertension.Cardiology journal · 2025Review
- Molecular Pathophysiology of Chronic Thromboembolic Pulmonary Hypertension: A Clinical Update from a Basic Research Perspective.Advances in respiratory medicine · 2024Review
- From Pulmonary Embolism to Chronic Thromboembolic Pulmonary Hypertension: A Pathophysiological Approach.Reviews in cardiovascular medicine · 2024Review
- Chronic Thromboembolic Pulmonary Artery Hypertension or Fibrosing Mediastinitis?JACC. Case reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare disease observed in a small proportion of patients after acute pulmonary embolism (PE). CTEPH has a high morbidity and mortality rate, related to the PH severity, and a poor prognosis, which mirrors the right ventricular dysfunction involvement. Pulmonary endarterectomy (PEA) reduces pulmonary vascular resistance, making it the treatment of choice and should be offered to operable CTEPH patients, as significant symptomatic and prognostic improvement has been observed. Moreover, these patients may also benefit from the advances made in surgical techniques and pulmonary hypertension-specific medication. However, not all patients are eligible for PEA surgery, as some have either distal pulmonary vascular obstruction and/or significant comorbidities. Therefore, surgical candidates should be carefully selected by an interprofessional team in expert centers. This review aims at making an overview of the risk factors and latest developments in diagnostic tools and treatment options for CTEPH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.